Skip to main content
رجوع
IRWD logo

Ironwood Pharmaceuticals, Inc.

جودة البيانات: 100%
IRWD
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
KWD 3.29
▲ KWD 0.25 (8.22%)
القيمة السوقية: 536.46M
نطاق اليوم
KWD 3.18 KWD 3.40
نطاق 52 أسبوعًا
KWD 0.53 KWD 5.78
حجم التداول
2,291,609
متوسط 50 يوم / 200 يوم
KWD 4.21 / KWD 2.36
الإغلاق السابق
KWD 3.04

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 22.3 0.4
P/B 2.9
ROE % 3.7
Net Margin % 8.1 3.9
Rev Growth 5Y % -8.0 10.0
D/E 0.2

السعر المستهدف للمحللين

Hold
KWD 4.800 +45.9%
Low: KWD 3.700 High: KWD 5.700
مكرر الربحية المستقبلي
2.6
ربحية السهم المستقبلية
KWD 1.280
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
460 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 0.605
KWD 0.596 – KWD 0.614
240 M 1
FY2029 KWD 0.480
KWD 0.473 – KWD 0.487
250 M 1
FY2028 KWD 1.560
KWD 1.537 – KWD 1.583
490 M 1

النقاط الرئيسية

Revenue declined -8.02% annually over 5 years
Earnings grew 2629.20% over the past year
Generating 127.01M in free cash flow
PEG of 0.01 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.70%
Cash machine — converts 528.83% of earnings into free cash flow

النمو

Revenue Growth (5Y)
-8.02%
Revenue (1Y)-15.72%
Earnings (1Y)2629.20%
FCF Growth (3Y)-16.73%

الجودة

Return on Equity
N/A
ROIC26.51%
Net Margin8.11%
Op. Margin40.10%

الأمان

Debt / Equity
N/A
Current Ratio1.13
Interest Coverage3.63

التقييم

P/E Ratio
22.34
P/B RatioN/A
EV/EBITDA7.74
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -15.72% Revenue Growth (3Y) -18.21%
Earnings Growth (1Y) 2629.20% Earnings Growth (3Y) N/A
Revenue Growth (5Y) -8.02% Earnings Growth (5Y) -53.83%
Profitability
Revenue (TTM) 296.15M Net Income (TTM) 24.02M
ROE N/A ROA 6.05%
Gross Margin 99.36% Operating Margin 40.10%
Net Margin 8.11% Free Cash Flow (TTM) 127.01M
ROIC 26.51% FCF Growth (3Y) -16.73%
Safety
Debt / Equity N/A Current Ratio 1.13
Interest Coverage 3.63 Dividend Yield 0.00%
Valuation
P/E Ratio 22.34 P/B Ratio N/A
P/S Ratio 1.81 PEG Ratio 0.01
EV/EBITDA 7.74 Dividend Yield 0.00%
Market Cap 536.46M Enterprise Value 918.81M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 296.15M 351.41M 442.74M 410.60M 413.75M
Net Income 24.02M 880,000.0 -1.00B 175.07M 528.45M
EPS (Diluted) 0.15 0.01 -6.45 0.96 3.21
Gross Profit 294.27M 343.86M 436.59M 409.18M 343.35M
Operating Income 118.76M 93.12M -945.43M 250.34M 232.26M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 396.90M 350.91M 471.07M 1.10B 1.13B
Total Liabilities 658.74M 652.24M 817.37M 448.14M 521.02M
Shareholders' Equity -261.83M -301.34M -346.30M 652.38M 605.91M
Total Debt 597.80M 599.48M 715.54M 415.92M 475.80M
Cash & Equivalents 215.46M 88.56M 92.15M 656.20M 620.13M
Current Assets 274.18M 182.37M 233.29M 780.63M 745.23M
Current Liabilities 242.22M 38.85M 276.10M 25.53M 161.70M